Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN

Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 192,296 shares of the life sciences company’s stock after selling 15,739 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of Illumina worth $25,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Empowered Funds LLC grew its holdings in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Illumina during the 2nd quarter valued at $621,000. CW Advisors LLC purchased a new stake in Illumina during the 2nd quarter valued at $275,000. Marshall Wace LLP boosted its position in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC grew its holdings in Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. UBS Group restated a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Evercore set a $150.00 price target on Illumina in a report on Friday, February 6th. JPMorgan Chase & Co. lowered their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $129.69.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.

Illumina Stock Down 3.9%

Shares of NASDAQ ILMN opened at $125.44 on Friday. The firm has a fifty day simple moving average of $124.88 and a two-hundred day simple moving average of $125.43. Illumina, Inc. has a 12 month low of $73.86 and a 12 month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $19.06 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts expect that Illumina, Inc. will post 5.12 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.